uMethod Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.56M
- Investors
-
3
uMethod General Information
Description
Provider of evidence-based, personalized treatment plan services intended to treat chronic diseases. The company's treatment plans propose the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to a subgroup of patients, instead of a one-drug-fits-all model, enabling patients to get the customized care that they need to transform their lives.
Contact Information
Website
www.umethod.comCorporate Office
- 9660 Falls of Neuse Road
- Suite 138-146
- Raleigh, NC 27615
- United States
Corporate Office
- 9660 Falls of Neuse Road
- Suite 138-146
- Raleigh, NC 27615
- United States
uMethod Timeline
uMethod Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 08-Dec-2025 | $4.56M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series C) | 06-Sep-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 06-Jul-2017 | $2.06M | $2.84M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Jul-2015 | $785K | $785K | Completed | Generating Revenue |
uMethod Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
uMethod Patents
uMethod Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210327588-A1 | Methods, systems, and devices for assessing the status of an individual's immune system | Inactive | 16-Apr-2020 | ||
| US-20170053088-A1 | Interactive and analytical mobile system that provides a dynamic tool for therapies to prevent and change the progression of dementia-related diseases | Inactive | 22-Aug-2015 | ||
| US-11257593-B2 | Interactive and analytical system that provides a dynamic tool for therapies to prevent and cure dementia-related diseases | Active | 22-Aug-2015 | ||
| US-12046369-B2 | Interactive and analytical system that provides a dynamic tool for therapies to prevent and cure dementia-related diseases | Active | 22-Aug-2015 | ||
| US-12676238-B2 | Interactive and analytical system that provides a dynamic tool for therapies to prevent and cure dementia-related diseases | Active | 22-Aug-2015 | G16H50/20 |
uMethod Signals
uMethod Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| NC Tweener Fund | Venture Capital | Minority | ||
| Quartus Capital Partners | Venture Capital | Minority | ||
| The Pink Ceiling | Venture Capital | Minority |
uMethod FAQs
-
When was uMethod founded?
uMethod was founded in 2013.
-
Where is uMethod headquartered?
uMethod is headquartered in Raleigh, NC.
-
What is the size of uMethod?
uMethod has 15 total employees.
-
What industry is uMethod in?
uMethod’s primary industry is Decision/Risk Analysis.
-
Is uMethod a private or public company?
uMethod is a Private company.
-
What is uMethod’s current revenue?
The current revenue for uMethod is .
-
How much funding has uMethod raised over time?
uMethod has raised $22.4M.
-
Who are uMethod’s investors?
NC Tweener Fund, Quartus Capital Partners, and The Pink Ceiling have invested in uMethod.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process